News | Investors | Join our team CONTACT US Rafael Holdings LEADERSHIP Rafael Holdings is focused on developing novel cancer and immune therapies. The company owns the Barer Institute, and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through the Barer Institute, the company is developing a pipeline of compounds focused on the regulation of cancer and immune metabolism. Rafael Holdings invests in novel cancer therapeutics that have the potential to improve and extend the lives of patients News Press Release Nov 22, 2021 Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus - READ MORE - News Coverage Nov 11, 2021 Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma New Trial Sites Open at Cleveland Clinic Children's and University of Michigan - READ MORE - Leadership Rafael Pharmaceuticals Lipomedix Pharmaceuticals Press Releases News Coverage Investors Contact Us Privacy Policy Disclaimer Copyright @2018 Rafael Holdings, Inc. All rights reserved

News | Investors | Join our team CONTACT US Rafael Holdings LEADERSHIP CONTACT US Rafael Holdings, Inc. 520 Broad Street Newark, NJ 07102 Email: invest@rafaelholdings.com | news@rafaelholdings.com Phone: (212) 658-1450 Business Development Contact David.Polinsky Chief Financial Officer Email: david.polinsky@rafaelholdings.com Leadership Rafael Pharmaceuticals Lipomedix Pharmaceuticals Press Releases News Coverage Investors Contact Us Privacy Policy Disclaimer Copyright @2018 Rafael Holdings, Inc. All rights reserved